Sitagliptin Phosphate (Januvia)

A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.

Also Known As:

Januvia; MK 0431; 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine; MK-0431; MK0431; Sitagliptin; Sitagliptin Monophosphate Monohydrate; Sitagliptin Phosphate Anhydrous; Sitagliptin Phosphate Monohydrate; 0431, MK; Anhydrous, Sitagliptin Phosphate; Monohydrate, Sitagliptin Monophosphate; Monohydrate, Sitagliptin Phosphate; Monophosphate Monohydrate, Sitagliptin; Phosphate Anhydrous, Sitagliptin; Phosphate Monohydrate, Sitagliptin; Phosphate, Sitagliptin

Networked: 1598 relevant articles (301 outcomes, 608 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - Sitagliptin Phosphate: 1598
        Metformin Hydrochloride Drug Combination Sitagliptin Phosphate: 8
        MK-626: 3
  - Pyrazines: 150
    - Sitagliptin Phosphate: 1598
      - Metformin Hydrochloride Drug Combination Sitagliptin Phosphate: 8
      - MK-626: 3

Experts

1.	Engel, Samuel S: 50 articles (01/2022 - 04/2010)
2.	Kaufman, Keith D: 39 articles (01/2022 - 02/2008)
3.	Holman, Rury R: 24 articles (01/2022 - 12/2013)
4.	Terauchi, Yasuo: 22 articles (12/2019 - 01/2010)
5.	Peterson, Eric D: 21 articles (01/2022 - 07/2015)
6.	Green, Jennifer B: 20 articles (07/2022 - 10/2010)
7.	Davies, Michael J: 20 articles (01/2017 - 12/2005)
8.	Kaufman, K D: 19 articles (06/2015 - 07/2008)
9.	Golm, Gregory T: 18 articles (01/2022 - 04/2010)
10.	Goldstein, Barry J: 18 articles (09/2016 - 08/2007)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 05/01/2011 - "In this study, sitagliptin treatment significantly and rapidly improved glycemic measures and was well tolerated in patients aged ≥ 65 years with type 2 diabetes." 01/01/2016 - " findings suggested that sitagliptin alone or in combination significantly improved serum TG and HDL-C levels in patients with type 2 diabetes mellitus." 01/01/2007 - "Improvements from baseline in mean glycosylated haemoglobin (HbA(1c)) were significantly greater with sitagliptin monotherapy than with placebo in patients with type 2 diabetes. " 11/01/2006 - "Sitagliptin significantly improved glycaemic control and was well tolerated in patients with type 2 diabetes mellitus who had inadequate glycaemic control on exercise and diet." 01/01/2014 - "GA is superior to HbA1c for evaluating the efficacy of sitagliptin treatment in patients with type 2 diabetes."
2.	Body Weight (Weight, Body) 06/01/2015 - "In this analysis of elderly patients with T2DM, compared with sulfonylurea, sitagliptin provided similar glycaemic efficacy with less hypoglycaemia and with body weight loss." 01/01/2017 - "Furthermore, 4th ICV injection of sitagliptin reduced 24h body weight gain and energy intake, with a selective suppression of high-fat diet, but not chow, intake. " 01/01/2017 - "Sixth-month evaluation revealed no difference between sitagliptin and non-sitagliptin groups in terms of weight, body mass index, and HbA1c (p>0.05). " 08/01/2016 - "Sitagliptin treatment led to a significant body weight loss of 1 kg per year. " 06/01/2015 - "Sitagliptin was weight-neutral; while the between-group difference in change from baseline in body weight was statistically significant, the modest difference may not be clinically meaningful. "
3.	Insulin Resistance 01/01/2018 - "This study indicates that sitagliptin significantly ameliorates the development of hepatic steatosis and insulin resistance in ob/ob mice by inhibiting inflammatory responses and activating autophagy via AMPK/mTOR signaling pathway." 04/01/2015 - "These studies show that sitagliptin can reverse memory impairment in high-fat-fed mice and is also associated with improved insulin sensitivity, enhanced hippocampal neurogenesis and reduced oxidative stress. " 03/01/2021 - "3) Good glycemic efficacy of sitagliptin is medicated through reduced insulin resistance as well as enhanced beta-cell functions. " 01/01/2017 - "Serum levels of RBP-4 were also markedly decreased in the sitagliptin treatment group, and more importantly it was positively correlated with improved insulin resistance parameters. " 01/01/2017 - "Our study supports a potentially promising role of sitagliptin in improving insulin resistance by decreasing RBP-4 in GDM-affected women."
4.	Inflammation (Inflammations) 10/15/2018 - "Sitagliptin has shown protective effects against intestinal I/R injury in rats through reduction of intestinal inflammation and apoptosis. " 09/01/2014 - "Sitagliptin also exerted protective effects against inflammation and pro-apoptotic state in the retina of diabetic rats. " 03/31/2023 - "These results demonstrate that sitagliptin ameliorates inflammation by inhibiting DPP-4 and consequently modulating the PTP1B-related JAK/STAT axis, leading to the alleviation of DN." 04/01/2022 - "This work shows that sitagliptin improved renal functions and histopathological changes, impeded inflammation, and oxidative stress and upregulated PI3K/AKT pathway which highlights its renoprotective effects in a rat model of DN." 11/01/2019 - "Therefore, the observed effects of sitagliptin occurred at least partly through an improvement in angiogenesis and the mitigation of inflammation. "
5.	Hyperglycemia 07/01/2011 - "Sitagliptin decreased the average glycemic level and also improved 24-h glycemic fluctuation, including postprandial hyperglycemia." 10/01/2019 - "The present study evaluated whether the dipeptidyl peptidase-4 inhibitor sitagliptin attenuates glomerular lesions and oxidative stress evoked by chronic hyperglycemia, by a mechanism independent of insulin secretion and glycemia normalization. " 12/01/2018 - "Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study." 01/01/2017 - "Larger studies are needed to determine the role of oral agents like sitagliptin to lower postprandial hyperglycemia with closed loop." 01/01/2021 - "Hyperglycemia was controlled with sitagliptin. "

Related Drugs and Biologics

1.	Metformin (Glucophage)
2.	Glucose (Dextrose)
3.	Insulin (Novolin)
4.	Dipeptidyl-Peptidase IV Inhibitors
5.	Liraglutide
6.	Exenatide (Byetta)
7.	glimepiride (Amarel)
8.	Pioglitazone (Actos)
9.	Glycated Hemoglobin (Glycosylated Hemoglobin)
10.	Insulin Glargine (Lantus)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Gastrectomy
4.	Aftercare (After-Treatment)
5.	Injections